CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2540 participants.

Also called NCT05931276

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,540 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05931276
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05931276. Randomized; no masking; primary purpose treatment. Start 2024-05-22 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
Acronym
BRAVO
Condition
End-Stage Kidney Disease
Condition
End-Stage Renal Disease
Intervention (Drug)
Metoprolol Succinate
Intervention (Drug)
Carvedilol
Lead sponsor
VA Office of Research and Development (class: US federal agency)

Record details

Record id
cardio:ct-nct05931276
Content hash
371fd29abde3e58bf16ee454c7e87cbb74290b385a3644f3b1cbce15a670acf4